The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients

The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients

Objective: To examine the kinetics of B cell subsets and activation markers in the early stage of belimumab treatment and their correction with treatment response.Methods: We enrolled 27 systemic lupus erythematosus (SLE) patients receiving 6 months belimumab treatment. Flow cytometry was used to te...

Full description

Bibliographic Details
Main Authors: Jing Wang, Bomiao Ju, Li Zhu, Hanchao Li, Jing Luo, Jing Zhang, Nan Hu, Lingfei Mo, Yanhua Wang, Ying Pan, Jing Huang, Xiaohong Lv, Dan Pu, Zhiming Hao, Lan He, Yuanyuan Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Pharmacology
Subjects:
B lymphocytes
belimumab
systemic lupus erythematosus
SYK (spleen tyrosine kinase)
Akt
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1080730/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1080730/full

Similar Items